Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 13;11(12):3377.
doi: 10.3390/jcm11123377.

Transcatheter Mitral Valve Repair or Replacement: Competitive or Complementary?

Zhang Xiling  1   2 , Thomas Puehler  1   2 , Lars Sondergaard  3 , Derk Frank  2   4 , Hatim Seoudy  4 , Baland Mohammad  1 , Oliver J Müller  2   4 , Stephanie Sellers  5   6   7 , David Meier  5   6   7 , Janarthanan Sathananthan  5   6   7 , Georg Lutter  1   2
Affiliations
Review

Transcatheter Mitral Valve Repair or Replacement: Competitive or Complementary?

Zhang Xiling et al. J Clin Med. .

Abstract

Over the last two decades, transcatheter devices have been developed to repair or replace diseased mitral valves (MV). Transcatheter mitral valve repair (TMVr) devices have been proven to be efficient and safe, but many anatomical structures are not compatible with these technologies. The most significant advantage of transcatheter mitral valve replacement (TMVR) over transcatheter repair is the greater and more reliable reduction in mitral regurgitation. However, there are also potential disadvantages. This review introduces the newest TMVr and TMVR devices and presents clinical trial data to identify current challenges and directions for future research.

Keywords: access; approach; endovascular; mitral insufficiency; mitral regurgitation; percutaneous; transcatheter mitral valve repair; transcatheter mitral valve replacement; transcatheter technology; transluminal.

PubMed Disclaimer

Conflict of interest statement

T.P. is a consultant for Abbott. G.L. is a consultant for Edwards Lifesciences and Abbott. D.F. is a consultant for Edwards Lifesciences and Medtronic and has received research funding from Edwards Lifesciences. M.S. is a consultant for Medtronic. J.S. is a consultant for Edwards Lifesciences, Boston Scientific and Medtronic and received speaker fees from Edwards. He has also received institutional research funds from Edwards Lifesciences and Medtronic. L.S. has received consultant fees and/or institutional research grants from Abbott, Boston Scientific, Medtronic, and SMT. D.M. is supported by the Swiss National Science Foundation (grant P2LAP3_199561). L.S. has received consultant fees and/or institutional research grants from Abbott, Boston Scientific, Medtronic and SMT All other authors have no commercial or financial relationships that could be construed as potential conflicts of interest.

Figures

Figure 1
Figure 1
Transcatheter Mitral Valve Repair Systems: (A) MitraClipTM device. Image courtesy of Abbott. (B) PASCAL system. Image courtesy of Edwards Lifesciences. (C) Cardioband system. Image courtesy of Edwards Lifesciences. (D) Mitralign system. Image courtesy of Mitralign Inc. (E) Carillon mitral contour system. Image courtesy of Cardiac Dimensions. (F) NeoChord system. Image courtesy of NeoChord Inc.
Figure 2
Figure 2
Transcatheter Mitral Valve Replacement Systems: (A) Tendyne prosthesis. Image courtesy of Abbott. (B) Tiara prosthesis (left: top view, right: side view). Image courtesy of Neovasc Inc. (C) Intrepid prosthesis. Image courtesy of Medtronic. (D) EVOQUE prosthesis. Image courtesy of Edwards Lifesciences. (E) SAPIEN M3 prosthesis. Image courtesy of Edwards Lifesciences. (F) HighLife prosthesis. Image courtesy of HighLife Medical.
Figure 2
Figure 2
Transcatheter Mitral Valve Replacement Systems: (A) Tendyne prosthesis. Image courtesy of Abbott. (B) Tiara prosthesis (left: top view, right: side view). Image courtesy of Neovasc Inc. (C) Intrepid prosthesis. Image courtesy of Medtronic. (D) EVOQUE prosthesis. Image courtesy of Edwards Lifesciences. (E) SAPIEN M3 prosthesis. Image courtesy of Edwards Lifesciences. (F) HighLife prosthesis. Image courtesy of HighLife Medical.
Figure 3
Figure 3
Selection of the most appropriate therapeutic strategy. CABG: coronary artery bypass grafting.
Figure 4
Figure 4
Transcatheter mitral valve delivery approaches: (a) transseptal, (b) transapical, (c) left atriotomy, (d) transaortic [101].
See this image and copyright information in PMC

References

    1. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., Enriquez-Sarano M. Burden of valvular heart diseases: A population-based study. Lancet. 2006;368:1005–1011. doi: 10.1016/S0140-6736(06)69208-8. - DOI - PubMed
    1. Badhwar V., Thourani V.H., Ailawadi G., Mack M. Transcatheter mitral valve therapy: The event horizon. J. Thorac. Cardiovasc. Surg. 2016;152:330–336. doi: 10.1016/j.jtcvs.2016.03.049. - DOI - PubMed
    1. Walther C., Fichtlscherer S., Holubec T., Vasa-Nicotera M., Arsalan M., Walther T. New developments in transcatheter therapy of mitral valve disease. J. Thorac. Dis. 2020;12:1728. doi: 10.21037/jtd.2019.12.137. - DOI - PMC - PubMed
    1. Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J., Iung B., Lancellotti P., Lansac E., Munoz D.R., et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Kardiol. Pol. 2018;76:1–62. doi: 10.5603/KP.2018.0013. - DOI - PubMed
    1. Mirabel M., Iung B., Baron G., Messika-Zeitoun D., Détaint D., Vanoverschelde J.L., Butchart E.G., Ravaud P., Vahanian A. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur. Heart J. 2007;28:1358–1365. doi: 10.1093/eurheartj/ehm001. - DOI - PubMed

LinkOut - more resources